ANZEMET DIN 02231379
Health Canada record
| Active ingredient(s) | DOLASETRON MESYLATE 100 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A04AA04 DOLASETRON |
| Original market date | 15-Aug-1997 |
| Current status date | 21-Apr-2014 |
| Source | Health Canada DPD |
Establishment licence of the holder
sanofi-aventis Canada Inc. — licence 101470, currently licensed, last inspection rating C (2026-02-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DOLASETRON MESYLATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02231378 | ANZEMET | SANOFI-AVENTIS CANADA INC | Tablet | DOLASETRON MESYLATE 50 MG | Cancelled Post Market |
| 02231380 | ANZEMET INJECTION 20 MG/ML | SANOFI-AVENTIS CANADA INC | Solution | DOLASETRON MESYLATE 20 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 7931 | 2006-05-04 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 1105 | 2000-06-16 | New Drug Submission (NDS) | |
| 3731 | 1997-05-21 | New Drug Submission (NDS) |
International API supply for DOLASETRON MESYLATE
2 active FDA Drug Master Files.
Request a quote for ANZEMET